Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network

The Informed Consent Action Network supports the request for a precautionary principle warning regarding acetaminophen use during pregnancy and labor. They provide a book as a comprehensive index of scientific literature to help the FDA identify and contextualize evidence regarding acetaminophen's potential neurodevelopmental risks.

The American Pharmacists Association (APhA) opposes the proposed action, arguing that it could undermine the integrity of the Vaccine Injury Compensation Program (VICP). They emphasize that the VICP provides essential liability protection for pharmacists and ensures a stable vaccine supply, warning that changes to eligibility criteria could increase unsubstantiated claims and diminish patient access to immunizations.

The commenter is submitting a peer-reviewed study by Tamaki et al. (2024) to support the requested acetaminophen warning. They argue that the study demonstrates unexpectedly high mammary transfer of acetaminophen into breast milk, necessitating expanded warning language for the full perinatal exposure window.

The commenter provides a scientific article from the Journal of Physiology to support the need for a prenatal warning regarding acetaminophen use. They argue that the drug crosses the fetal blood-brain barrier and that prolonged exposure may pose a neurodevelopmental risk to the fetus.

The commenter provides a scientific review from The Journal of Physiology to support a petition regarding prenatal acetaminophen safety. They argue that because acetaminophen readily crosses the placenta and enters the fetal brain, pregnant women should receive clear warning language and informed-consent guidance.

An individual commenter supports the consideration of next-generation analgesic technologies, specifically mentioning SynCore Biotechnology's SNP-810, as a safer alternative to conventional acetaminophen. They argue that products with differentiated metabolic pathways and reduced toxic burden should be evaluated under distinct regulatory frameworks rather than being grouped with legacy products.

The Informed Consent Action Network (ICAN) argues that sibling-control analyses in prenatal neurodevelopment research are often unstable and potentially biased, and therefore should not be used to dismiss potential risks from prenatal acetaminophen. They advocate for the FDA to weigh these studies alongside other evidence to justify a precautionary prenatal warning.

The Informed Consent Action Network supports the citizen petition requesting a precautionary warning on prenatal acetaminophen use. They argue that biomarker-based studies provide more reliable evidence of adverse neurodevelopmental outcomes by reducing recall bias and exposure misclassification compared to self-reporting studies.

The Informed Consent Action Network, represented by Siri & Glimstad LLP, supports the proposed action. They argue that a new study on rodent models provides biologically plausible evidence of developmental neurotoxicity from in utero acetaminophen exposure, justifying a precautionary warning during pregnancy.

Americans for Scientific Integrity supports the proposed action by providing supplemental evidence that suggests precautionary risk communication regarding prenatal acetaminophen exposure is appropriate. They argue that recent studies showing structural brain differences and potential risks for ADHD and autism, combined with biological considerations regarding metabolic windows, warrant clearer information for pregnant individuals and clinicians.